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Background: Colorectal cancer mortality presents world-wide variation. In rectal cancers presenting a
complete/nearly-complete tumor response (ypT0/ypTis) following neoadjuvant treatment, the features
correlated to nodal metastases and relapses still need to be defined.
Methods: An international cohort study enrolling ypT0/ypTis rectal cancers surgically treated from 2012
to 2017 was conducted. A propensity matching was used to balance nodal-positive and nodal-negative
patients and statistical analyses were performed to investigate survivals, using a bootstrap model for
internal validation. The features correlated with nodal metastasis were studied. Countries with partici-
pating centers were ranked using the World Bank (WBI), Human Development (HDI) and Global Gender
Gap (GGG) indexes to compare survivals.
Results: 680 ypT0/ypTis from 52 European, Australian, Indian and American Institutions were analyzed.
Mean follow-up was of 30.4 months. 96.5% were treated with total mesorectal excision, 7.2% were nodal-
positive and 8.8% relapsed. Distal cancers (HR 0.71 95%CI: 0.56-0.91) and nodal metastasis and nodal
metastasis (HR 3.85 95%CI:1.12e13.19) correlated with worse DFS, whereas a younger age was of
borderline significance (HR 0.95 95%CI:0.91e0.99). The bootstrap analysis validated the model on 5000
repetitions. A short-course radiotherapy (OR 0.18 95%CI:0.09e0.37) correlated with the occurrence of
nodal metastasis. Those countries classified in the low/medium-WBI, medium-HDI and lower-GGG ranks
documented worse DFS curves (respectively p< 0.0001, p < 0.0001 and p 0.0002). However, the clinical
stages were similar and patients from medium-HDI countries received more adjuvant chemotherapy
than the others (p< 0.0001).
Conclusion: Sub-groups at risk for relapses and nodal metastasis were identified. A global variation exists
also when benchmarking a rectal cancer complete regression.
© 2019 Published by Elsevier Ltd.g the Scientific Symposium
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.10.010Introduction
Recent data from the Global Cancer Observatory (GLOBOCAN
2018), documented that colorectal cancer is still the third most
frequent cancer and the second cause of cancer related mortality,
however its incidence and mortality present a relevant world-wide
variation [1,2].
Rectal cancers account for about 30% of colorectal cancers [3]
and represent a field of relevant surgical, clinical and biological
investigations. Over the last three decades the approach to rectalterm outcomes of ypT0 rectal cancers, European Journal of Surgical
L. Lorenzon et al. / European Journal of Surgical Oncology xxx (xxxx) xxx2cancer radically changed: the improvements achieved lead to the
introduction of total mesorectal excision (TME) and neoadjuvant
(chemo)radiation treatments [4,5]. Nevertheless, the state-of-the
art is continuously evolving as the effects of neoadjuvant treat-
ments started to emerge in literature [6].
In particular, tumor down-staging following neoadjuvant
treatment could result in a complete response, defined as clinical
response (absence of residual primary tumor clinically detectable,
cT0) or pathological response (absence of viable tumor cells within
the rectal wall in the surgical specimen, ypT0) [7], occurring in
about 10e20% of the patients who were treated with neoadjuvant
therapy prior to surgery [8,9].
In this subset of patients, the improved survival outcomes
[10,11] and the benefits of avoiding major surgical procedures, are
encouraging a more conservative approach including watch and
wait protocols [12,13] or a local excision of the residual tumor scar
[14].
Despite the achievement of a complete response could be
acknowledged as a milestone, a number of issues still need to be
addressed, in particular in relation to the surgical strategy, the
identification of factors correlated to relapses and tumor regres-
sion, and the incidence and impact of a residual nodal disease.
A pilot multicenter investigation was recently conducted in this
field investigating the pattern of survivals of rectal cancer patients
presenting a complete or nearly complete tumor response after
neoadjuvant therapy. Patients were treated using local excision or
TME in Italy and Spain and results were highly promising, in
particular in disclosing differences in survivals between patients
assessed as nodal negative (ypN0) or presenting residual nodal
metastases (ypNþ) [6].
On the other hand, significant differences are emerging con-
cerning survivals of rectal cancers in different countries, surprising
also when comparing Norther European countries [15]. The
geographic discrepancies concerning surgical quality and access to
surgical care are currently a prioritizing issue, as widely declared by
the Lancet Commission on Global Surgery [16]. On this extent, the
National Institute for Health Research (NIHR) Global Health
Research Unit on Global Surgery is in the process of establishing
research hubs in low- and middle-income countries; a four-stage
modified Delphy study identified three priority areas for future
research, including the access to surgery, surgical oncology and
peri-operative surgical care. With respect to the second domain,
the aim was to define a resource-weighted quality assurance
framework for cancer surgery; the research questions included,
among the others, the identification of quality indicators and the
role of multidisciplinary team meeting (MDT) in delivering cancer
care. Accordingly, it was agreed that “a global observational cohort
study was needed to benchmark care pathways and outcomes in low-
income against high-income countries. This study would capture data
on patient pathways, including availability of diagnostic and thera-
peutic services, short-term surgical outcomes and longer-term cancer-
specific outcomes”. Colorectal cancer was assessed as a top priority
along with breast and gastric cancers [17].
This study focused on COmplete pathological ReSponse rectal
CAncer (CORSiCA) and aimed to investigate if nodal metastases
independently affected prognosis and the clinical variables corre-
lated with the occurrence of pathologic nodes. In addition, the
global variations in the outcomes of rectal cancers presenting a
complete pathological response were studied.
Methods
Design
This retrospective cohort study was promoted by the EuropeanPlease cite this article as: Lorenzon L et al., Global variation in the long-
Oncology, https://doi.org/10.1016/j.ejso.2019.10.010Society of Surgical Oncology (ESSO) Young Alumni Club (EYSAC).
The project received approval by ESSO board and was registered on
clinicaltrials.gov on November 2017 (ClinicalTrials.gov Identifier:
NCT03351959). CORSiCA was publicized using ESSO network and
social media and it was officially launched on December 1st, 2017
with a global call closing onMarch 2017. Actions were also taken by
EYSAC steering committee members to spread the project; each
center could participate a junior (<40 years) member for data
collection and a senior investigator for data validation [6]. No limit
of enrollment was fixed for patients’ registration, nor there was a
minimum number of patients/center. The project was notified at
the PI IRB institution (protocol n. 50973/17). The PI also standard-
ized the core documentation, in order to have all sites working with
the same version of the protocol and notified the centers with the
project status updates using regular newsletters.Patients
All patients with a rectal cancer surgically treated from 2012 to
2017, presenting a pathological surgical report consistent with ypT0
(absence of cancerous cells in the rectal wall) or ypTis (intra-
mucosal carcinoma with no extension into the muscularis
mucosae) following neoadjuvant treatment could be enrolled,
independently from the neoadjuvant scheme, type of surgical
resection or nodal status.Clinical and pathological records
All the clinical and pathological records were de-identified by
recruiting centers and pooled in a common database by the PI using
a consecutive number. For the purpose of data collection, a data-
base was designed adhering to the STROBE Statement [18]. The
records included: demographics, tumor location and diameter,
presence or not of large bowel obstruction, clinical staging (cTNM
and clinical mesorectal fascia involvement e cMRF- defined as the
presence or absence of tumor/nodal metastases involving meso-
rectal fascia on pre-treatment imaging scans) obtained using
computer tomography (CT), magnetic resonance imaging (MRI)
and/or endoscopic ultrasound (Endo-US). Also, the neoadjuvant
protocols were collected, and patients classified into: short-course
radiotherapy (SHORT RT) or a long-course chemo-radiotherapy
(CHT-RT) sub-groups. The total dose of radiationwas recorded (Gy),
along with possible dose reductions or treatment interruptions.
The radiological assessment following neoadjuvant treatment was
recorded together with the interval time to surgery (measured in
weeks). With respect to the surgical approaches, low-anterior
resection, Miles resection and trans-anal TME were all catego-
rized as TME procedures. On the other hand, patients undergoing a
trans-anal endoscopic microsurgery resection, a trans-anal minimal
invasive resection or a traditional trans-anal excision, were all
grouped in the local excision group. The records included also the
pathologic data (ypN stage, lymph-nodes harvested in the surgical
specimen e LNH), the rate of adjuvant chemotherapy treatments
and the long term oncological outcomes.Outcome measures
The outcomemeasures included patients’ survivals and residual
nodal disease (ypNþ). The follow-up was registered with the end-
points of overall survival (OS, any cause of death) and disease free
survival (DFS, first recurrence after surgical resection). The relapses
were differentiated in local relapses (rectal/anastomotic site), pel-
vic relapses (nodal) and relapses at distant sites (i.e. lung/liver).term outcomes of ypT0 rectal cancers, European Journal of Surgical
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Continuous variables were analyzed using means and standard
deviations (SD), tested for normal distribution using Kolmogorov-
Smirnov normality test and compared accordingly. Categorical var-
iables were analyzed using frequencies and percentage values and
compared using Chi-square test. In order to control potential con-
founders that could affect the outcomes of interest, a propensity
score matching [19] was used to generate two different treatment
groups with balanced distribution of baseline features. Propensity
scores resulted from logistic regression with dependent variable
being the presence of nodal metastases. Covariates included age at
diagnosis, gender and tumor location. The patients were matched
one-to-two with the nearest-neighbor method using a caliper dis-
tance of 30% of the standard deviation of the logit of the estimated
propensity score to ensure good matches. The balance between the
two groups was assessed using the relative multivariate imbalance
measure L1 as proposed by Iacus, King and Porro [20e22].
Survival analyses were conducted using the Kaplan-Meier
method with log-rank test and Cox regression analyses. The Haz-
ard risk and its relative 95% confidence interval (95%CI) was esti-
mated for each variable using the Cox proportional univariate
model adopting the most suitable prognostic category as reference
group. A multivariate Cox proportional hazard model was also
developed using stepwise regression (forward selection). Enter
limit and remove limit were p¼ 0.05 and p¼ 0.10, respectively,
with significance defined at the p¼ 0.05 level. In order to avoid
overfitting, a bootstrapmethod (resampling with replacement) was
used for internal validation of the DFS univariate model. Ten in-
dependent procedures, each containing 1000 bootstrap samples,Fig. 1. CORSiCA Project. A. Registered Institutions map and trend over time. B. Num
Please cite this article as: Lorenzon L et al., Global variation in the long-
Oncology, https://doi.org/10.1016/j.ejso.2019.10.010were performed. In order to further challenge the model, a larger
procedure with 5000 repetitions was carried out.
To test if putative variables correlated with a ypN þ outcome, a
logistic regression was performed in the TME group including:
gender, age, tumor location, cT, cN, cMRF stages and neoadjuvant
schemes. The logistic regression was used since it has been docu-
mented an extremely valuable model in epidemiologic studies,
allowing multiple variables to be analyzed in the same time. The
odds ratio (OR) obtained expresses the probability of an event
favorable to an outcome and the probability of an event against the
same outcome; accordingly, a large OR means that the chance of a
particular group is much greater than that of the reference group
and vice-versa [23].
Finally, the geographic variation was investigated ranking
countries with participating centers according to the World Bank
Index (WBI) [24], the human development index (HDI: a United
Nations' composite statistic including life expectancy, education,
and income indices) [25] and the Global Gender Gap (GGG) Index
provided by the World Economic Forum which measure progress
towards gender parity across economic participation and oppor-
tunity, educational attainment, health and survival, and political
empowerment [26]. Briefly, the countries were ranked into high
income countries (HIC), uppermiddle income countries (UMIC) and
lower middle income countries (LMIC) according to the WBI; very
high/high HDI and medium HDI according to the United Nations’
index and finally in the upper (1e50), middle (51e100) or lower
(101e149) ranks of the GGG list report. The indexes were then
compared for the differentiation of HIC-UMIC/very high-high HDI/
upper and middle GGG ranks vs LMIC/medium HDI/lower GGG
ranks using the weighted kappa inter-agreement.ber of participating Institutions according to different continents and countries.
term outcomes of ypT0 rectal cancers, European Journal of Surgical
Table 1
Clinical and pathological features of CORSiCA population.
Sex N %
F 254.0 37.4
M 425.0 62.5
Total 680 100.0
M/F 1.7
Age (years)
Mean (SD) 60.0 14.2
Distance from the anal verge (cm)
Mean (SD) 5.8 3.2
cT Stage N %
cT1 4.0 0.6
cT2 97.0 14.3
cT3 512.0 75.3
cT4 67.0 9.9
Total 680.0 100.0
cN Stage N %
cN0 177.0 26.0
cN þ 503.0 74.0
Total 680.0 100.0
acMRF N %
Negative 503.0 74.0
Positive 177.0 26.0
Total 680.0 100.0
bNeoadjuvant treatment N %
CHT-RT 625.0 91.9
SHORT-RT 55.0 8.1
Total 680.0 100.0
cSurgical Treatment N %
TME 656.0 96.5
Local excision 24.0 3.5
Total 680.0 100.0
ypN Stage N %
ypN þ 47 7.2
ypN0 609 92.8
Total 656.0 100.0
Adjuvant Chemotherapy N %
Performed 341 50.1
Not performed 339 49.9
Total 680.0 100.0
Follow up (months)
Mean (SD) 30.4 20.4
Relapses N %
Distant 38.0 63.3
Local 9.0 15.0
Distant þ Local 1.0 1.7
Pelvic 7.0 11.7
Unknown 5.0 8.3
Total 60.0 100.0
a cMRF: clinical mesorectal fascia involvement.
b Neo-adjuvant treatment e CHT-RT (long course chemoradiation) SHORT-RT
(short course radiotherapy followed by immediate or delayed surgery).
c Surgical treatment: TME-total mesorectal excision.
L. Lorenzon et al. / European Journal of Surgical Oncology xxx (xxxx) xxx4All statistical analyses were centralized by the PI, blinded to the
recruiting centers and obtained using MedCalc (MariaKerke,
Belgium) version 10.2.0.0 and SPSS (IBM, Armonk USA) version 21.0
software. All tests were performed two-tailed and a p value< 0.05
was considered as statistically significant.
Results
Between December and March 2017, 88 Institutions from all
over the world registered in the study, however exclusively 52 of
them (59.0%) performed as recruiting centers. About 93% of these
52 institutions were European, whereas non-European centers
included Australia, India and Argentina, Fig. 1. Nine Institutions
were also enrolled in the pilot investigation [6]. Mean age of the
junior investigators was 32.9± 4.2 years whereas the seniors were
about 15 years older (mean age 48.6± 8.9 years); the centers were
mostly categorized as University hospitals (67.3%), performing high
volume colorectal surgery (92.3% declared >80 colorectal re-
sections/year) and with colorectal MDTs scheduled on a regular
basis in 90.4% of the cases. Nine-hundred and seven ypT0/ypTis
were registered, but patients with incomplete clinical records (date
of surgery, age, clinical staging, neoadjuvant scheme, follow-up
data, adjuvant therapy) and clinical stage IV were excluded, leav-
ing 680 patients for data analysis. Overall, 77 patients, 11.3% of the
case series, were enrolled in the same Institutions as the pilot
investigation. Clinical and surgical data of the cohort are detailed in
Table 1. Clinical staging was performed using MRI in 77.8% of the
patients, CT scan in 97.3%, and Endo-US in only 33.8% of the cases.
The vast majority of the rectal cancers were clinically assessed as
cT3/cT4 (84.6%), cNþ (74.0%), cMRF negative (74.0%) before the
neoadjuvant treatment.
As expected, a prevalence of males was reported (M/F 1.7) with a
mean age of 60.0 years± 14.2 years. The majority of the patients
presented a low rectal cancer (mean distance from the anal verge
5.8± 3.2 cm), and the neoadjuvant treatment consisted mostly of
long-course CHT-RT (91.9%). The tumors were mainly treated using
TME, with only 3.5% of patients undergoing a local excision. Among
TME patients, 7.1% were node positive. Some 85.4% of the SHORT RT
sub-group was treated with delayed surgery at a mean interval of
12.9± 11.9 weeks. Mean follow up was 30.4± 20.4 months and
50.1% of the patients were subsequently treated with adjuvant
chemotherapy following surgery. Sixty relapses were reported
(8.8%), thirty-eight at a distant site. The mean time to relapse was
20.9± 13.3 months.
Nodal status and survival outcome
The propensity method was conducted to match ypN þ patients
with ypN0 patients from the TME group (ypN þ experimental
group ¼ 1, ypN0 control group ¼ 0; Matching Ratio 1:2), using the
following co-variates: age, gender and tumor location. The analyses
yielded 141 matched patients (1:2 ratio; 47 ypN þ and 94 ypN0).
The L1 test measure was larger in the unmatched sample (0.764)
than in the matched sample (0.553) indicating that the two groups
were well balanced across all the variables considered. A lower
rectal cancer (HR 0.71 95%CI: 0.56-0.91) and ypNþ (HR 3.85 95%
CI:1.12e13.19) were variables correlated with worse DFS, whereas
younger age was documented as a variable of borderline signifi-
cance (HR 0.95 95%CI:0.91e0.99), Table 2. Although only the tumor
location provided significant results in the multivariate model, all
the three parameters were tested using a bootstrap.
A bootstrap method (resampling with replacement) was used
for internal validation of the DFS univariate analysis. Ten inde-
pendent procedures, each containing 5000 bootstrap samples,
were performed and all of them validated the Cox proportionalPlease cite this article as: Lorenzon L et al., Global variation in the long-
Oncology, https://doi.org/10.1016/j.ejso.2019.10.010hazard results, Table 3.
Nodal metastases
Table 4 shows results of logistic regression analysis. Also in this
case the analysis was restricted to 656 TME patients. The logistic
regression documented that a short-course radiotherapy (OR 0.18
95%CI:0.09e0.37) and younger age (OR 0.98 95%CI:0.96e0.99)
correlated with the end-point of nodal metastasis, although age
disclosed borderline values. Consistently with the effect of the
radio-chemo-therapy, the long-course group had a significantly
smaller nodal harvest (mean 12.3 vs 16.7, Kruskal-Wallis p-value
0.001), Suppl Fig. 1.
ypT0 in a global surgery frame
The patients from countries ranking in the LMIC, medium HDIterm outcomes of ypT0 rectal cancers, European Journal of Surgical
Table 2
Cox proportional hazard model and nodal status: results from ypN þ vs ypN0 PSM analysis.
Endpoint OSa
Variable Comparison HR 95%CI p-value
Gender F vs M 0.78 0.20e3.15 0.730
Age Continuous variable 1.03 0.98e1.09 0.222
Tumor location Continuous variable 0.96 0.77e1.21 0.744
cNeoadjuvant treatment CHR-RT vs SHORT-RT 23.91 NE e
ypN ypN þ vs ypN0 1.65 0.44e6.14 0.458
End-point DFSb
Univariate model Multivariate model
Variable Comparison HR 95%CI p-value
Gender F vs M 0.39 0.08e1.82 0.231
Age Continuous variable 0.95 0.91e0.99 0.008
Tumor location Continuous variable 0.96 0.56e0.91 0.006 0.71 (0.56e0.91) p¼ 0.006
cNeoadjuvant treatment CHR-RT vs SHORT-RT 0.88 0.11e7.09 0.908
ypN ypN þ vs ypN0 3.85 1.12e13.19 0.032
Forward selection model.
a OS: Overall Survival 9 events.
b DFS: Disease Free Survival 11 events
c Neo-adjuvant treatment e CHT-RT (long course chemoradiation) SHORT-RT (short course radiotherapy followed by immediate or delayed surgery).
Table 3
Bootstrap model-internal validation of DFS analysis in ypN þ vs ypN0 PSM sample.
End-point DFS
Variable Comparison HR 95%CI p-value Bootstrap Results
N samples¼ 5000
Age Continuous variable 0.95 0.91e0.99 0.008 Validated (10/10)
Tumor location Continuous variable 0.71 0.56e0.91 0.006 Validated (10/10)
ypN ypN þ vs ypN0 3.85 1.12e13.19 0.032 Validated (10/10)
Table 4
Logistic regression with the end-point of ypNþ.
Variable Comparison OR 95%CI p-value
Gender F vs M 0.87 0.47e1.63 0.665
Age Continuous variable 0.98 0.96e0.99 0.040
Tumor location Continuous variable 0.99 0.90e10.9 0.796
cT 1 þ 2 vs 3 1.67 0.58e4.80 0.343
1 þ 2 vs 4 2.10 0.57e7.77 0.266
cN cN þ vs cN0 1.66 0.76e3.63 0.204
acMRF Positive vs Negative 1.17 0.61e2.25 0.630
bNeoadjuvant treatment CHR-RT vs SHORT-RT 0.18 0.09e0.37 < 0.001
a cMRF: clinical mesorectal fascia involvement.
b Neo-adjuvant treatment e CHT-RT (long course chemoradiation) SHORT-RT
(short course radiotherapy followed by immediate or delayed surgery).
L. Lorenzon et al. / European Journal of Surgical Oncology xxx (xxxx) xxx 5and those in the lower ranks of the GGG index documented worse
DFS curves (respectively p value< 0.0001,p< 0.0001 and p 0.0002),
Fig. 2. Interestingly, the clinical stages at presentation were re-
ported similar in high and low income countries, p 0.183 (Table 5).
Also, the patients from medium HDI countries received more
adjuvant chemotherapy than the others, Table 5. Finally, the WBI
and HDI indexes showed an optimal concordance in discriminating
medium and lower-middle income ranks (weighted kappa 1.000),
whereas both two indexes presented a moderate concordance vs
GGG (weighted kappa 0.774), Suppl Table 1.
Discussion
The achievement of a complete pathologic response in the
surgical specimen following neoadjuvant treatment is a benchmark
of the progress made so far in rectal cancer treatment. Several
manuscripts documented the benefits of complete response in
terms of survival [6,10] and clinical research is moving forward to
explore the benefits of an organ preservation.Please cite this article as: Lorenzon L et al., Global variation in the long-
Oncology, https://doi.org/10.1016/j.ejso.2019.10.010This study identified a group of “ugly features” in patients
treated with TME; in particular, patients with distal and nodal
positive tumors, reported a worse DFS; these results were strongly
validated by the bootstrap model. Although in this study a younger
age was documented an independent variable affecting prognosis
of borderline significance, the literature reports that the incidence
of colorectal cancer in individuals <50 years is escalating, and the
tumor behavior in this sub-group has been described as particularly
aggressive [27,28].
The presence of residual nodal disease in the in ypT0 sub-group
herein reported was similar to past studies in this field, ranging
between 6.7% and 8.7% [6,8]. A recent analysis documented that the
rate of ypT0-ypN þ could be low to three percent if patients were
clinically staged as nodal negative on pre-treatment MRI [29]. Past
research reported also a strict correlation between the residual ypT
and ypN following neoadjuvant treatment but no correlation was
documented between ypN and tumor location [30]. In CAO/ARO/
AIO-04 trial, patients where noted to have no metastases below
the tumor, and more nodal metastases in the peritumoral meso-
rectum than proximal to the tumor-site [31]. These results were not
supported by the present findings where ypN þ correlated with
short-course radiotherapy but not with cT/cN stages or tumor
location; of note ypN þ patients were registered in Australia, Ger-
many, Greece, India, Italy, Poland, Portugal, Romania and Spain
(data not shown).
These findings have significant implications when considering
organ-preservation strategies. Nowadays, these approaches
encompass a number of treatments ranging from endoscopical/
surgical local excisions to a full watch and wait approach [32,33].
Moreover, they imply the identification of a clinical complete
response using radiological/radiomics criteria of tumor regression
[34e37].
Undoubtedly, an organ preservation has the advantage ofterm outcomes of ypT0 rectal cancers, European Journal of Surgical
Fig. 2. Kaplan Meier curves with the end-point of DFS in ypT0 patients according to country development indexes. Curves were censored at 60 months; A.World Bank Index (WBI),
log-rank test p < 0.0001; B. Human Development Index (HDI), log-rank test p< 0.0001; C. Gender Gap Index, log-rank test p 0.0002.
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Table 5
Clinical Stage and adjuvant treatments according to the economic and development
indexes.
high/very high
HDI
medium HDI p value
cStage N % % %
cStage 1 39.0 6.9 3.0 2.6
cStage 2 109.0 19.3 26.0 22.6 0.183
cStage 3 417.0 73.8 86.0 74.8
Total 565.0 100.0 115.0 100.0
Adjuvant Chemotherapy N % N %
Performed 235.0 41.6 106.0 92.2 < 0.0001
Not performed 330.0 58.4 9.0 7.8
Total 565.0 100.0 115.0 100.0
L. Lorenzon et al. / European Journal of Surgical Oncology xxx (xxxx) xxx 7ensuring a better quality of life, although the follow-up schemes are
more intensive and the local tumor regrowth has been acknowl-
edged as a critical issue [13,38,39]. Recent results from the Inter-
CoRe consortium investigated the factors affecting local regrowth
in 600 patients managed with watch and wait, using an individual
participant data meta-analysis. The cumulative incidence of local
regrowth was of 21.4% and correlated with cT stage, reporting,
however, high levels of heterogeneity between studies [40]. Similar
results were also obtained in the OnCoRe Project, although local
regrowth rates were higher (34%) [41].
Possibly because of the difficulties in defining a clinical
response, but also due to the limitations of the researches pub-
lished so far, the organ preservation strategy is not currently rec-
ommended in routinely practice out of clinical studies. According to
the most recent ESMO guidelines this approach could be consid-
ered when a clinical response is achieved in high-risk/fragile pa-
tients; however, “a small increased oncological risk of pelvic and
metastatic disease exist, although the prognosis is excellent even
without surgery” [42]. The results from large studies, such as the
IWWD registry [43,44] or the STAR-TREC trial [45], will provide
more information and will help in selecting eligible patients.
A particular aspect of this large data-set is the involvement of
several countries from four continents, aiming to frame the results
of complete response in a global surgery context. As previously
reported, surgery is the gold standard treatment of solid tumors,
but currently less than one quarter of patients currently receive a
safe, affordable and timely procedures, since surgical care in low-
income countries is largely neglected [16]. However, this issue is
affecting also northern Europe, since survival from colorectal can-
cer in England and Denmark was recently reported lower than in
Norway and Sweden [15]. Remarkably, this study reported optimal
survivals in high-income ranking countries according to three
different, but concordant, indexes. A significant negative correla-
tion between relapses and low-income countries was documented
on Kaplan Meier analyses, despite all patients performed neo-
adjuvant therapy and all of them received a surgical treatment (at
least with a local excision).
If a late presentation could explain the variances in disease free
survivals, CORSiCA study disclosed that no particular differencewas
noted concerning clinical stages at presentation among different
countries. Still, survival outcomes could be explained on the basis of
differences in the tumor biology, but patients were registered in
four continents in a precise time frame. This study highlighted also
that medium-HDI countries perform more adjuvant chemotherapy
comparing high/very high-HDI countries, consistently with the
multimodal management. Despite almost the totality of the In-
stitutions participating in this project, self-declared to perform >80Please cite this article as: Lorenzon L et al., Global variation in the long-
Oncology, https://doi.org/10.1016/j.ejso.2019.10.010colorectal resections/year and to discuss patients in MDTs on a
regular basis, it should be acknowledged that volume is not the
only key indicator of quality and the rise in surgical standards as
well as the achievement of a multimodal treatment in a process of
continuous auditing were the elements that changed the state of
the art in rectal cancer management [46,47].
Recently, the HDI was used to compare countries on the basis of
the surgical curriculum they offered. It was documented that the
length of training and the availability of domestic surgical oncology
fellowships had a positive correlation with HDI ranks [48]. On this
basis, the leaders of the Society of Surgical Oncology and European
Society of Surgical Oncology developed a global curriculum to
incorporate the domains considered to be essential in surgical
oncology [49].
Limitations of this study include the observational design and
the impossibility of conducting molecular analyses to investigate
features correlated with residual nodal disease. However, the large
sample of patients from all over the world allowed to obtain sig-
nificant clinical data, as recently achieved in other large interna-
tional audits [50,51].
Finally, the schemes of neoadjuvant treatment for rectal cancer
varies considerably across different countries [52]. A recent study in
this field demonstrated that between 2007 and 2014 the use of
SHORT RT ranged from 5% in Belgium to 75% in the Netherlands,
whereas CHT-RT was used in the 87% of patients in Belgium and in
the 15% of stage II-III rectal cancers in the Netherlands [52]. How-
ever, the vast majority of neoadjuvant protocols are based on CHT-
RT schemes, consistently with our results, although they may
present variation in the rate of ypT0 produced. These results are in
relation to the radiation dose, the chemotherapy drugs and the
interval to surgery [53]; all these features may vary also in the same
Institution through the years. During the study period, some 17687
rectal cancers where surgically treated across participating In-
stitutions (mean 340.1± 338.8 patients, ranging 52e1760 surgical
procedures/Institution). On this basis, the rate of complete re-
sponses reported in this study is consistent with the overall pop-
ulation included. Of note, even if patients were treated by different
means and modalities, the entire project focused on the ultimate
effect of the neoadjuvant treatment: the occurrence of a complete
rectal cancer regression, thus the cases selected across sites where
homogeneous for this feature.
The findings reported with CORSiCA project have important
oncological and oncopolicy implications. This project identified a
particular sub-group of responders patients at risk for relapses,
including patients with distal tumors and those reporting the
persistence of nodal disease. In particular and with respect of the
nodal persistence, a short course radiotherapy was documented in
relationwith ypNþ. All these features should be taken into account
when considering a more conservative approach.
Finally, since the clinical stages and rates of adjuvant treatment
were comparable, two possible reasons could explain the
geographic discrepancies, one and highly speculative being the
difference in the tumor biology that was not here investigated. The
second reason could be a possible shortfall in the provision of
surgical oncology standards. Raising the standards in surgical
oncology quality should improve the long-term outcomes globally,
also when the effect of the multimodal treatment of rectal cancer
achieve a complete tumor regression. However, the addition of
molecular features would help in better understanding the inter-
national variation and possible inequalities.Funding
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